The Zhitong Finance App learned that on Friday, Moderna (MRNA.US) rose more than 5% to $254.36. According to the news, Moderna announced results for the third quarter of 2026. According to financial reports, the company's total revenue was US$1,313 million, up 29% year on year, far higher than market expectations of about US$885 million; net profit of US$162 million, reversing losses compared to a net loss of US$200 million in the same period last year; and diluted earnings per share of US$0.38, which was significantly better than the market's expected loss of 1.25 US dollars per share.

The company raised its full-year guidance. The 2026 revenue growth rate was raised sharply from the previous “up to 10%” to 15% to 25%. It is estimated that about half of the revenue will come from the US and half from the international market; the R&D cost guide will be lowered from about US$2.9 billion to about US$2.7 billion; and the year-end cash and investment guidance will be raised from US$4.7 billion to US$5.2 billion to US$8.1 billion to US$8.3 billion.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.